Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese Biotechs Partner Up 18.2-Targeting ADCs Amid Intense Domestic Competition

Executive Summary

Following rapid R&D growth in the area, China now has roughly 40 drug candidates targeting Claudin 18.2 across various modalities including monoclonal antibodies, antibody-drug conjugates and bispecific antibodies, with a number of contenders now striking international licensing-out deals in a bid to get ahead of rivals.

You may also be interested in...



Competition Grows In Claudin18.2 As AstraZeneca Seals Antibody Conjugate Deal

Already a major player in the field thanks to Enhertu, AstraZeneca is doubling down in gastric cancer with the new antibody-drug conjugate deal with China’s KYM Biosciences.

Finance Watch: Sun Shines On Biotech Stocks As J.P. Morgan Ends

Public Company Edition: Also, Johnson & Johnson’s consumer health spin-out Kenvue filed paperwork to get the ball rolling on an initial public offering. In addition, Geron raised $198m and Madrigal accessed more than $300m after positive trial readouts, but layoffs were revealed by Editas, Elevation, Nabriva and others.

Astellas Reports Second Phase III Win With Zolbetuximab In Stomach Cancer

The anti-Claudin-18.2 agent plus chemotherapy improves progression-free survival in inoperable or metastatic stomach cancer, following a similar Phase III readout in November.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel